Nonhematopoietic Nrf2 dominantly impedes adult progression of sickle cell anemia in mice

JCI Insight

Volumn 1, Issue 4, 2016, Pages

  Ghosh, Samit ^a   Ihunnah, Chibueze A ^a   Hazra, Rimi ^a   Walker, Aisha L ^a   Hansen, Jason M ^b   Archer, David R ^c   Owusu Ansah, Amma T ^a   Ofori Acquah, Solomon F ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b BRIGHAM YOUNG UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85026580481     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.81090     Document Type: Article

References (63)

1. Platt OS, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994; 330(23):1639-1644.
2. Hamideh D, Alvarez O. Sickle cell disease related mortality in the United States (1999-2009). Pediatr Blood Cancer. 2013; 60(9):1482-1486.
3. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood. 2010; 115(17):3447-3452.
4. Telfer P, et al. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica. 2007; 92(7):905-912.
5. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood. 2004; 103(11):4023-4027.
6. Gaston MH, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med. 1986; 314(25):1593-1599.
7. Lanzkron S, Carroll CP, Haywood C Jr. Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. Public Health Rep. 2013; 128(2):110-116.
8. Yanni E, Grosse SD, Yang Q, Olney RS. Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002. J Pediatr. 2009; 154(4):541-545.
9. Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med. 2011; 41(6 suppl 4):S398-S405.
10. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013; 10(7):e1001484.
11. Fleming AF. The presentation, management and prevention of crisis in sickle cell disease in Africa. Blood Rev. 1989; 3(1):18-28.
12. Wierenga KJJ, Hambleton IR, Lewis NA, Unit SC. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet. 2001; 357(9257):680-683.
13. de Montalembert M, Guitton C. Transition from paediatric to adult care for patients with sickle cell disease. Br J Haematol. 2014; 164(5):630-635.
14. Nouraie M, et al. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica. 2013; 98(3):464-472.
15. Muller-Eberhard U, Javid J, Liem HH, Hanstein A, Hanna M. Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases. Blood. 1968; 32(5):811-815.
16. Gladwin MT, Ofori-Acquah SF. Erythroid DAMPs drive inflammation in SCD. Blood. 2014; 123(24):3689-3690.
17. Lee JM, et al. Nrf2, a multi-organ protector?. FASEB J. 2005; 19(9):1061-1066.
18. Thimmulappa RK, et al. Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDOImidazolide. Biochem Biophys Res Commun. 2006; 351(4):883-889.
19. Lee JM, Chan K, Kan YW, Johnson JA. Targeted disruption of Nrf2 causes regenerative immune-mediated hemolytic anemia. Proc Natl Acad Sci U S A. 2004; 101(26):9751-9756.
20. Neumann CA, et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature. 2003; 424(6948):561-565.
21. Schacter L, Warth JA, Gordon EM, Prasad A, Klein BL. Altered amount and activity of superoxide dismutase in sickle cell anemia. FASEB J. 1988; 2(3):237-243.
22. Chiu D, Lubin B. Abnormal vitamin E and glutathione peroxidase levels in sickle cell anemia: evidence for increased susceptibility to lipid peroxidation in vivo. J Lab Clin Med. 1979; 94(4):542-548.
23. Tatum VL, Chow CK. Antioxidant status and susceptibility of sickle erythrocytes to oxidative and osmotic stress. Free Radic Res. 1996; 25(2):133-139.
24. Morris CR, et al. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood. 2008; 111(1):402-410.
25. Sangokoya C, Telen MJ, Chi JT. microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood. 2010; 116(20):4338-4348.
26. Flurkey K, Currer JM, Harrison DE. The mouse in aging research. In: Fox JG, Barthold SW, Davisson MT, Newcomer CE, Quimby FW, Smith AL, eds. The Mouse in Biomedical Research. Vol 3. 2nd ed. Burlington, Massachusetts, USA: Elsevier Academic Press; 2007:637-672.
27. Hansen JM, Zhang H, Jones DP. Differential oxidation of thioredoxin-1, thioredoxin-2, and glutathione by metal ions. Free Radic Biol Med. 2006; 40(1):138-145.
28. Kato GJ, et al. Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. Br J Haematol. 2005; 130(6):943-953.
29. Kwak MK, Wakabayashi N, Itoh K, Motohashi H, Yamamoto M, Kensler TW. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J Biol Chem. 2003; 278(10):8135-8145.
30. Corada M, et al. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci U S A. 1999; 96(17):9815-9820.
31. Ghosh S, et al. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J Clin Invest. 2013; 123(11):4809-4820.
32. Kaul DK, Fabry ME, Suzuka SM, Zhang X. Antisickling fetal hemoglobin reduces hypoxia-inducible factor-1α expression in normoxic sickle mice: microvascular implications. Am J Physiol Heart Circ Physiol. 2013; 304(1):H42-H50.
33. Okumura MJ, Heisler M, Davis MM, Cabana MD, Demonner S, Kerr EA. Comfort of general internists and general pediatricians in providing care for young adults with chronic illnesses of childhood. J Gen Intern Med. 2008; 23(10):1621-1627.
34. Treadwell M, Telfair J, Gibson RW, Johnson S, Osunkwo I. Transition from pediatric to adult care in sickle cell disease: establishing evidence-based practice and directions for research. Am J Hematol. 2011; 86(1):116-120.
35. Clark LT. Issues in minority health: atherosclerosis and coronary heart disease in African Americans. Med Clin North Am. 2005; 89(5):977-1001.
36. Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA. Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 2010; 303(13):1288-1294.
37. Jordan L, Swerdlow P, Coates TD. Systematic review of transition from adolescent to adult care in patients with sickle cell disease. J Pediatr Hematol Oncol. 2013; 35(3):165-169.
38. Andemariam B, Owarish-Gross J, Grady J, Boruchov D, Thrall RS, Hagstrom JN. Identification of risk factors for an unsuccessful transition from pediatric to adult sickle cell disease care. Pediatr Blood Cancer. 2014; 61(4):697-701.
39. Hayes RJ, Beckford M, Grandison Y, Mason K, Serjeant BE, Serjeant GR. The haematology of steady state homozygous sickle cell disease: frequency distributions, variation with age and sex, longitudinal observations. Br J Haematol. 1985; 59(2):369-382.
40. Grieninger G, Liang TJ, Beuving G, Goldfarb V, Metcalfe SA, Muller-Eberhard U. Hemopexin is a developmentally regulated, acute-phase plasma protein in the chicken. J Biol Chem. 1986; 261(33):15719-15724.
41. Adisa OA, Hu Y, Ghosh S, Aryee D, Osunkwo I, Ofori-Acquah SF. Association between plasma free haem incidence of vaso-occlusive episodes acute chest syndrome in children with sickle cell disease. Br J Haematol. 2013; 162(5):702-705.
42. Vinchi F, et al. Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases. Circulation. 2013; 127(12):1317-1329.
43. Keleku-Lukwete N, et al. Amelioration of inflammation and tissue damage in sickle cell model mice by Nrf2 activation. Proc Natl Acad Sci U S A. 2015; 112(39):12169-12174.
44. Rojo AI, et al. Signaling pathways activated by the phytochemical nordihydroguaiaretic acid contribute to a Keap1-independent regulation of Nrf2 stability: Role of glycogen synthase kinase-3. Free Radic Biol Med. 2012; 52(2):473-487.
45. Bryan HK, Olayanju A, Goldring CE, Park BK. The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol. 2013; 85(6):705-717.
46. Numazawa S, Ishikawa M, Yoshida A, Tanaka S, Yoshida T. Atypical protein kinase C mediates activation of NF-E2-related factor 2 in response to oxidative stress. Am J Physiol Cell Physiol. 2003; 285(2):C334-C342.
47. Jain AK, Jaiswal AK. Phosphorylation of tyrosine 568 controls nuclear export of Nrf2. J Biol Chem. 2006; 281(17):12132-12142.
48. Jain AK, Jaiswal AK. GSK-3beta acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2. J Biol Chem. 2007; 282(22):16502-16510.
49. Yuan X, et al. Butylated hydroxyanisole regulates ARE-mediated gene expression via Nrf2 coupled with ERK and JNK signaling pathway in HepG2 cells. Mol Carcinog. 2006; 45(11):841-850.
50. Clements CM, McNally RS, Conti BJ, Mak TW, Ting JP. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci U S A. 2006; 103(41):15091-15096.
51. Chen W, et al. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell. 2009; 34(6):663-673.
52. Camus SM, et al. Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease. Blood. 2015; 125(24):3805-3814.
53. Haupt HM, Moore GW, Bauer TW, Hutchins GM. The lung in sickle cell disease. Chest. 1982; 81(3):332-337.
54. Graham JK, Mosunjac M, Hanzlick RL, Mosunjac M. Sickle cell lung disease and sudden death: a retrospective/prospective study of 21 autopsy cases and literature review. Am J Forensic Med Pathol. 2007; 28(2):168-172.
55. Carden D, Xiao F, Moak C, Willis BH, Robinson-Jackson S, Alexander S. Neutrophil elastase promotes lung microvascular injury and proteolysis of endothelial cadherins. Am J Physiol. 1998; 275(2 pt 2):H385-H392.
56. de Zeeuw D, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013; 369(26):2492-2503.
57. Wu LC, Sun CW, Ryan TM, Pawlik KM, Ren J, Townes TM. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood. 2006; 108(4):1183-1188.
58. Pamplona A, et al. Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Nat Med. 2007; 13(6):703-710.
59. Hemmi H, et al. The roles of two IκB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med. 2004; 199(12):1641-1650.
60. Seixas E, et al. Heme oxygenase-1 affords protection against noncerebral forms of severe malaria. Proc Natl Acad Sci U S A. 2009; 106(37):15837-15842.
61. Jones DP, et al. Glutathione measurement in human plasma. Evaluation of sample collection, storage and derivatization conditions for analysis of dansyl derivatives by HPLC. Clin Chim Acta. 1998; 275(2):175-184.
62. Verhoeven D, Teijaro JR, Farber DL. Pulse-oximetry accurately predicts lung pathology and the immune response during influenza infection. Virology. 2009; 390(2):151-156.
63. Ghosh S, Tan F, Ofori-Acquah SF. Spatiotemporal dysfunction of the vascular permeability barrier in transgenic mice with sickle cell disease. Anemia. 2012; 2012:582018.